Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 03-2025 | 03-2024 | 03-2023 | 03-2022 | |
| Sales | 12 | 6 | 156 | 9 | 0 |
| Cost of Goods | 5 | 59 | 106 | 10 | N/A |
| Gross Profit | 8 | -53 | 51 | -1 | N/A |
| Operating Expenses | 6,412 | 6,083 | 6,653 | 5,741 | 1,734 |
| Operating Income | -6,400 | -6,077 | -6,497 | -5,733 | -1,734 |
| Interest Expense | 62 | 58 | 27 | 16 | 15 |
| Other Income | 529 | -69 | -216 | 291 | -1 |
| Pre-tax Income | -5,932 | -6,204 | -6,739 | -5,458 | -1,750 |
| Income Tax | -900 | -137 | N/A | N/A | N/A |
| Net Income Continuous | -5,032 | -6,067 | -6,739 | -5,458 | -1,750 |
| Minority Interests | -8 | -6 | -6 | 0 | -41 |
| Net Income | $-5,024 | $-6,061 | $-6,734 | $-5,458 | $-1,709 |
| EPS Basic Total Ops | -12.64 | -40.62 | -84.00 | -128.25 | -45.00 |
| EPS Basic Continuous Ops | -12.66 | -40.66 | -83.99 | -128.36 | -45.75 |
| EPS Diluted Total Ops | -12.64 | -40.62 | -84.00 | -128.25 | -45.00 |
| EPS Diluted Continuous Ops | -12.66 | -40.66 | -83.99 | -128.36 | -45.75 |
| EPS Diluted Before Non-Recurring Items | -12.64 | -40.50 | -84.00 | -127.50 | N/A |
| EBITDA(a) | $-5,961 | $-5,733 | $-6,393 | $-5,733 | $-1,734 |